Kodiak (Nasdaq: KOD), a biopharmaceutical company, announced on Thursday that it has completed enrolment in its BEACON Phase three clinical trial of KSI-301, the company's anti-VEGF antibody biopolymer conjugate, for the treatment of macular edema due to retinal vein occlusion.

The product is an investigational anti-VEGF therapy based on Kodiak's Antibody Biopolymer Conjugate Platform and is aimed at maintaining potent and effective drug levels in ocular tissues for longer than present available agents. The company's aim with KSI-301 is to produce a new first-line agent to improve results for patients with retinal vascular diseases and to allow earlier treatment and prevention of vision loss for patients with diabetic eye disease.

The KSI-301 clinical programme is aimed at evaluating KSI-301's durability, efficiency and safety in wet AMD, DME, RVO and non-proliferative DR (without DME) via clinical studies that run in parallel.

The clinical programme is being carried out at 150 plus study sites in over 10 countries. The company is developing the product and owns global rights to it.